Molecular imaging predicts trastuzumab‐deruxtecan (T‐ DX d) response in head and neck cancer xenograft models
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Abdullah Bin Naveed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Vanderbilt University, Nashville, TN, USA. Hauptthemen laut MEDLINE: Trastuzumab, Head and Neck Neoplasms, Immunoconjugates, Molecular Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Erb‐b2 receptor tyrosine kinase 2 ( ERBB2 ; also known as HER2 ) expression is observed in 25–40% of head and neck squamous cell carcinomas (HNSCC), yet there are no anti‐ HER2 therapies under evaluation for HNSCC, as conventional cytostatic anti‐ HER2 antibodies have had limited effectiveness and levels of HER2 overexpression are lower in HNSCC tumors compared to breast cancer. Trastuzumab‐deruxtecan (T‐DXd; Enhertu) is a HER2 ‐targeting antibody‐drug conjugate (ADC) comprising an anti‐ HER2 monoclonal antibody, a cleavable linker, and a potent topoisomerase I inhibitor payload, and has shown promising results in very low HER2‐ expressing tumors. We compare the efficacy of T‐DXd, trastuzumab‐emtansine (ADC comprising an anti‐ HER2 antibody and microtubule inhibitor, T‐DM1; Kadcyla) and trastuzumab (Herceptin) therapy in HNSCC with low and absent HER2 expression in vitro and in vivo . In vitro treatment of a low HER2 ‐expressing human HNSCC cell line (FaDu) with T‐DXd resulted in dose‐dependent cell death (IC50 values of 9856 ng·mL −1 ). T‐DXd treatment of FaDu and UMSCC‐47 (low HER2 ‐expressing cell line) mouse xenografts displayed antitumor activity ( P = 0.0001 and 0.015 respectively). When comparing T‐DXd to other approved anti‐ HER2 therapies, only FaDu mice treated with T‐DXd showed a reduction in tumor growth ( P = 0.0012). In UMSCC‐1 cells (absent HER2 expression), the drug failed to accumulate in tumors and showed no measurable antitumor effect, in contrast to FaDu xenografts, where drug accumulation in the tumor correlated with a therapeutic response. T‐DXd treatment yielded antitumor activity in FaDu and UMSCC‐47 tumors, highlighting the potential for T‐DXd efficacy in low HER2‐ expressing tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Vanderbilt University, Nashville, TN, USA.
- Department of Surgery, Vanderbilt University, Nashville, TN, USA.
ORCID-Profile: Abdullah Bin Naveed, Marisa Hom
Zitieren
APA
Naveed, A. B., Mani, L., Mirza, M. B., McAdoo, A., Kondo, T., Tanaka, H., Meeks, N., Rosenthal, E., & Hom, M. (2025). Molecular imaging predicts trastuzumab‐deruxtecan (T‐ DX d) response in head and neck cancer xenograft models. Molecular Oncology. https://doi.org/10.1002/1878-0261.70056
Vancouver
Naveed AB, Mani L, Mirza MB, McAdoo A, Kondo T, Tanaka H, et al. Molecular imaging predicts trastuzumab‐deruxtecan (T‐ DX d) response in head and neck cancer xenograft models. Molecular Oncology. 2025. doi:10.1002/1878-0261.70056
BibTeX
@article{Naveed2025,
author = {Naveed, Abdullah Bin and Mani, Lucas and Mirza, Muhammad Bilal and McAdoo, Ashtyn and Kondo, Takahito and Tanaka, Hidenori and Meeks, Nicole and Rosenthal, Eben and Hom, Marisa},
title = {Molecular imaging predicts trastuzumab‐deruxtecan (T‐ DX d) response in head and neck cancer xenograft models},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70056}
}
EUVIMED